Clover Corporation’s (ASX:CLV) N3RO trial shows improvement in IQ of premature infants

• Clover Corporation (CLV) announces the release of new results from its clinical research study called the N3RO trial, showing early indication that Clover’s proprietary emulsion high DHA improved cognitive development
• The N3RO clinical research study commenced in 2012 and half the enrolled babies were administered Clover’s proprietary emulsion high in the Omega-3 fatty acid DHA as a supplement to their nutrition
• Further analysis of the results compiled in the N3RO trial will determine next steps for the program
• CLV shares slip 1.77 per cent, trading at $1.39

Clover Corporation (CLV) has released new results from its clinical research study called the N3RO trial, showing that Clover’s proprietary emulsion high DHA improved cognitive development.

The N3RO clinical research study commenced in 2012 after receiving funding support from the National Health and Medical Research Council and product support from Clover Corporation.

Infants born before 29 weeks of gestational age were enrolled with the final results available when the full report is compiled.

Over the course of the project, Clover Corporation has invested around $1.24 million in product development, professional services and people.

The N3RO trial follows on from positive outcomes in a previous Phase III trial named DINO, which showed premature infants whose diet was supplemented with higher DHA showed improved cognitive development in girls at 18 months.

The results also showed reduced oxygen requirement at 36 weeks in boys and reduced incidence of hay fever later in their development.

“We are encouraged in this early report of the top-line results from the study. We remain
committed to better understanding the full data set as we consider potential paths forward for the DHA emulsion product,” said Peter Davey, CEO & Managing Director of Clover Corporation.

During the N3RO trial, Clover’s proprietary emulsion high in the Omega-3 fatty acid DHA was administered to half of these babies as a supplement to their nutrition, along with standard treatments currently considered optimal for their successful development.

The rest of the group received a placebo emulsion in replacement for the DHA emulsion and a variety of parameters indicating the health and development of the treated infants were measured.

Recent regulations in the European Union and pending changes to China legislation for Chinese sold infant formula provide opportunities for Clover’s additional growth in the future.

Further analysis of the results compiled in the N3RO trial will determine next steps for the program.

CLV shares slipped 1.77 per cent, trading at $1.39 as of 2:34 pm AEDT.